Evaluation of S100A8/A9 and neutrophils as prognostic markers in metastatic melanoma patients under immune-checkpoint inhibition by Yasmin F Melzer, Nadine L Fergen, Christian Mess, Julia-Christina Stadler, Glenn Geidel, Ysabel A Schwietzer, Julian Kött, Klaus Pantel, Stefan W Schneider, Jochen Utikal, Ewa Wladykowski, Sabine Vidal-y-Sy, Alexander T Bauer, Christoffer Gebhardt

“…Serum S100A8/A9 levels and neutrophil counts at baseline (T0) and during treatment (T3) correlated with reduced progression-free survival (PFS). Elevated S100A8/A9 levels at T0 and T3 negatively impacted overall survival (OS). …”
Get full text

The concerted actions of microRNA-29a and interferon-β modulate complete Freund's adjuvant-induced inflammatory pain by regulating the expression of type 1 interferon receptor, int... by Chien-Cheng Liu, Kuo-Chuan Hung, Yu-Yu Li, Eagle Yi-Kung Huang, Chin-Chen Chu, Lok-Hi Chow, Ping-Heng Tan

“…Treatment with an miR-29a inhibitor alleviated CFA-induced mechanical allodynia and thermal hyperalgesia by Day 5 (P<0.001, n=9), concomitant with upregulation of IFNR1 and ISG15 expression, and downregulation of p-ERK (IFNR1; CFA 5 days + miR-29a inhibitor vs CFA 5 days; mean difference [95% CI]: 30.00 [20.31–39.69]; ISG15 conjugates; CFA 5 days + miR-29a inhibitor vs CFA 5 days, mean difference [95% CI]: 1.000 [0.9144–1.086]; free ISG15, mean difference [95% CI]: 2.402 [2.171–2.633]; p-ERK; CFA 5 days + miR-29a inhibitor vs CFA 5 days, mean difference [95% CI]: −32.00 [−34.10 to −29.90], P<0.001, n=9). …”
Get full text

Association between dietary patterns and glycemic control in type II diabetes mellitus patients by Ye Qiang, Xingchen Lu, Yuchao Zhang

“…In patients with the hyperglycemic drug and insulin free, higher PC2 levels were related to lower odds of hyperglycemia (OR: 0.45, 95% CI: 0.21–0.96). …”
Get full text

Neuroprotective role of epigallocatechin-3-gallate, albeginin and melanoxetin in alzheimer's disease by Arif Malik, Mehreen Hassan, Sulayman Waquar, Muhammad Wasim, Anam Naz, Faryal M. Awan, Muhammad T. Khan, Ali I. Khawaja, Sumera Zaib, Jamshed Iqbal, Ayesha Zahid, Marvi Marvi, Javeid Iqbal, Heng Wang, Dong-Qing Wei

“…Phytochemicals are considered safer alternatives and have shown significant efficacy in inhibiting cholinesterase, scavenging free radicals, inhibiting amyloid-β neurotoxicity, reducing inflammation, and interacting with neurotransmitters, thereby slowing down the progression of AD. …”
Get full text

Editorial by Ann-Kristin Kölln, Antony Mason, Maria Lenk, Jörg Tremmel, Markus Rutsche

“…As an alternative, he proposes the creation of incentives for young people to join parties and trade unions, such as free membership. In the book review section, Emily Ford assesses Richard Katz and Peter Mair’s Democracy and the Cartelization of Political Parties (2018, OUP). …”
Get full text

Pan-tumor analysis to investigate the obesity paradox in immune checkpoint blockade by Evan J Lipson, Ludmila Danilova, Elizabeth M Jaffee, Won Jin Ho, Mark Yarchoan, Yasser Ged, Jean Hoffman-Censits, Jennifer Durham, Sanjay Bansal, Chester Kao, Rajat Mohindra, Stephanie L Alden, Tanguy Y Seiwert, Soren Charmsaz, Howard L Li, Kabeer Munjal, Hua-Ling Tsai, Alexei Hernandez, Erin M Coyne, Rachel Garonce-Hediger, Laura Tang, Marina Baretti, Kathryn Howe, G Scott Chandler, Madelena Brancati, Aanika Warner, Ervin Griffin, Mari Nakazawa, Chris Thoburn, Jennifer Gizzi, Nicole E Gross, Elsa Hallab, Sarah S Shin, Aditi Guha

“…Compared with non-obese patients, obese patients had superior progression-free survival (HR: 0.44 (95% CI: 0.24 to 0.81), p=0.01) and overall survival (OS) (HR: 0.24 (95% CI: 0.07 to 0.80), p=0.02). …”
Get full text

Thesis Overview by Editor-in-Chief jCEC

“… [EN] Publish your “Thesis Overview” free of charge with us. In this case, the author, doctor or master, can publish a synthesis of their dissertation or thesis, in the form of a scientific article. …”
Get full text

Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS by Thomas Cluzeau, Fabio Guolo, Edmond Chiche, Paola Minetto, Ramy Rahme, Sarah Bertoli, Luana Fianchi, Jean-Baptiste Micol, Michele Gottardi, Pierre Peterlin, Sara Galimberti, Xavier Thomas, Giuliana Rizzuto, Olivier Legrand, Michela Rondoni, Emmanuel Raffoux, Giambattista Bertani, Alexis Caulier, Michelina D’Argenio, Caroline Bonmati, Atto Billio, Caroline Lejeune, Barbara Scappini, Arnaud Pigneux, Patrizia Zappasodi, Christan Recher, Francesco Grimaldi, Lionel Ades, Roberto M. Lemoli

“…These data provide the rationale for the 2 ongoing studies evaluating CPX-351 vs 7+3 in non–MRC-AML and non–t-AML using MRD as the primary end point for ALFA-2101 phase 2 clinical trial and event-free survival for AMLSG 30-18 phase 3 clinical trial.…”
Get full text

Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the Che... by Enriqueta Felip, David P. Carbone, Martin Reck, Luis Paz-Ares, Yong Yuan, Nan Hu, Niels Reinmuth, Xiaoqing Zhang, Thomas John, Ying Cheng, Shun Lu, Manuel Cobo, Michael Schenker, Tudor-Eliade Ciuleanu, Stéphanie Bordenave, Oscar Juan-Vidal, Juliana Menezes, Eduardo Richardet, Hideaki Mizutani, Bogdan Zurawski, Aurelia Alexandru, Javed Mahmood, Tuli De, Irene Santi, John R. Penrod, Adam Lee

“…Assessments included OS, progression-free survival, and objective response rate. Exploratory analyses included efficacy by tumor PD-L1 expression and histology and in patients who discontinued nivolumab plus ipilimumab with chemotherapy due to treatment-related adverse events (TRAEs), and a treatment-switching adjustment analysis using inverse probability of censoring weighting.Results With a 47.9-month minimum follow-up for OS, nivolumab plus ipilimumab with chemotherapy continued to prolong OS over chemotherapy in all randomized patients (HR 0.74, 95% CI 0.63 to 0.87; 4-year OS rate: 21% versus 16%), regardless of tumor PD-L1 expression (HR (95% CI): PD-L1&lt;1%, 0.66 (0.50 to 0.86) and ≥1%, 0.74 (0.60 to 0.92)) or histology (squamous, 0.64 (0.48 to 0.84) and non-squamous, 0.80 (0.66 to 0.97)). …”
Get full text

Immune monitoring of trabectedin therapy in refractory soft tissue sarcoma patients - the IMMUNYON study by Paulo Rodrigues-Santos, Paulo Rodrigues-Santos, Paulo Rodrigues-Santos, Paulo Rodrigues-Santos, Paulo Rodrigues-Santos, Paulo Rodrigues-Santos, Jani Sofia Almeida, Jani Sofia Almeida, Jani Sofia Almeida, Jani Sofia Almeida, Jani Sofia Almeida, Jani Sofia Almeida, Luana Madalena Sousa, Luana Madalena Sousa, Luana Madalena Sousa, Patrícia Couceiro, Patrícia Couceiro, Patrícia Couceiro, Patrícia Couceiro, António Martinho, Joana Rodrigues, Ruben Fonseca, Manuel Santos-Rosa, Manuel Santos-Rosa, Manuel Santos-Rosa, Manuel Santos-Rosa, Manuel Santos-Rosa, Paulo Freitas-Tavares, José Manuel Casanova, José Manuel Casanova, José Manuel Casanova, José Manuel Casanova, José Manuel Casanova

“…This study evaluates Trabectedin therapy in 22 refractory STS patients, analyzing progression-free survival (PFS) and immune responses. Immune monitoring included deep immunophenotyping (200+ parameters), gene expression profiling (103 genes), and soluble proteome analysis (99 analytes). …”
Get full text

Le mobilier en cuir antique et médiéval du boulevard Dr Henri-Henrot à Reims/Durocortorum by Martine Leguilloux

“…Other models of Sculponeae style (mules and clogs) footwear are absent from this material, such as the one with raised edges and a network of straps usually referred to as “carbatina”, but others, rarer, are present, as is the case for “mules” (wherein the foot is free in the rear portion of the shoe, but entirely covered in the front), as well as shoes with cork soles. …”
Get full text

Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas by Gohar S. Manzar, Chelsea C. Pinnix, Stephanie O. Dudzinski, Kathryn E. Marqueen, Elaine E. Cha, Lewis F. Nasr, Alison K. Yoder, Michael K. Rooney, Paolo Strati, Sairah Ahmed, Chijioke Nze, Ranjit Nair, Luis E. Fayad, Michael Wang, Loretta J. Nastoupil, Jason R. Westin, Christopher R. Flowers, Sattva S. Neelapu, Jillian R. Gunther, Bouthaina S. Dabaja, Susan Y. Wu, Penny Q. Fang

“…Median overall survival (OS) was 22.1 months (6.6-not reached) and the median progression-free survival (PFS) was 7.4 months (5.5-30). OS/PFS were 80% (66-99)/78% (64-87) at 1-year, and 59% (44-71)/54% (40-67) at 2-years, respectively. …”
Get full text

The prognosis and metabolite changes of NSCLC patients receiving first‐line immunotherapy combined chemotherapy in different M1c categories according to 9th edition of TNM classifi... by Liang Zheng, Fang Hu, Wei Nie, Jun Lu, Bo Zhang, Jianlin Xu, Shuyuan Wang, Ying Li, Xiaoxuan Zheng, Wei Zhang, Yinchen Shen, Runbo Zhong, Tianqing Chu, Baohui Han, Hua Zhong, Xueyan Zhang

“…The relationship between metastatic patterns and progression‐free survival (PFS) in patients undergoing combination therapy was analyzed using univariate and multivariate Cox regression models. …”
Get full text

Cancer cells avoid ferroptosis induced by immune cells via fatty acid binding proteins by Maria Angelica Freitas-Cortez, Fatemeh Masrorpour, Hong Jiang, Iqbal Mahmud, Yue Lu, Ailing Huang, Lisa K. Duong, Qi Wang, Tiffany A. Voss, Claudia S. Kettlun Leyton, Bo Wei, Wai-Kin Chan, Kevin Lin, Jie Zhang, Efrosini Tsouko, Shonik Ganjoo, Hampartsoum B. Barsoumian, Thomas S. Riad, Yun Hu, Carola Leuschner, Nahum Puebla-Osorio, Jing Wang, Jian Hu, Michael A. Davies, Vinay K. Puduvalli, Cyrielle Billon, Thomas P. Burris, Philip L. Lorenzi, Boyi Gan, James W. Welsh

“…Clinical trial data revealed that higher FABP7 expression correlates with poorer overall survival and progression-free survival in patients undergoing immunotherapy. …”
Get full text

Development of a framework to structure decision-making in environmental and occupational health: A systematic review and Delphi study by Emily Senerth, Paul Whaley, Elie Akl, Brandy Beverly, Pablo Alonso-Coello, Ezza Jalil, Jayati Khattar, Nicole R. Palmer, Andrew Rooney, Holger J. Schünemann, Kristina A. Thayer, Katya Tsaioun, Rebecca L. Morgan

“…Panelists rated the relevance and wording of each consideration on a 7-point Likert scale and provided free-text comments during both phases. Considerations that did not meet predetermined thresholds were excluded. …”
Get full text

Dental and oral health assessments in the German National Cohort (NAKO) by Stefanie Samietz, Katrin Borof, Katrin Hertrampf, Ghazal Aarabi, Antonio Ciardo, Hannah Finke, Daniel Hagenfeld, Jan Kühnisch, Maurice Rütters, Sebastian-Edgar Baumeister, Stefan Lars Reckelkamm, Ti-Sun Kim, Thomas Kocher, Wolfgang Ahrens, Hermann Brenner, Carina Emmel, Beate Fischer, Amand Führer, Karin Halina Greiser, Jasmin Grischke, Kathrin Günther, Volker Harth, Stefanie Jaskulski, André Karch, Thomas Keil, Yvonne Kemmling, Alexander Kluttig, Lilian Krist, Oliver Kuss, Michael Leitzmann, Claudia Meinke-Franze, Karin B. Michels, Nadia Obi, Anette Peters, Nicole Pischon, Tobias Pischon, Sabine Schipf, Börge Schmidt, Henning Teismann, Stefan Rupf, Birte Holtfreter

“…An initial inspection of the data showed that the median number of present teeth was 27, of which on average 6.9 teeth were healthy and caries-free. Average mean PD was 1.92 mm. An orthodontic treatment was reported by 35.5% of participants. …”
Get full text

Sex and outcomes of patients with microsatellite instability-high and BRAF V600E mutated metastatic colorectal cancer receiving immune checkpoint inhibitors by Michael Hoffmeister, Hermann Brenner, Chiara Cremolini, Sara Lonardi, Filippo Pietrantonio, Julien Taieb, David Tougeron, Robyn L Ward, Marco Vitellaro, Thierry André, Pierre Laurent-Puig, Jitendra Jonnagaddala, Francesca Bergamo, Raghav Sundar, Claire Gallois, Michael J Overman, Jakob Nikolas Kather, Lisa Salvatore, Romain Cohen, Rossana Intini, Priya Jayachandran, Miriam Koopman, Javier Ros, Marwan Fakih, Vincenzo Nasca, Giacomo Mazzoli, Jeanine M L Roodhart, Filippo Ghelardi, Elena Elez, Durgesh Wankhede, Marta Ligero, Joseph Zhao, Koen Zwart, Jeroen Derksen, Nicholas Hawkins, Javier Carmona

“…Finally, we explored two public microarray and RNA-seq datasets from patients with non-metastatic or metastatic MSI-H CRC to gain translational insights on the association between sex, BRAF status and immune contextures/ICI efficacy.Results Although no differences were observed between females and males either overall or in the BRAF wild-type cohort, male sex was associated with inferior progression-free survival (PFS) and overall survival (OS) in the BRAF mutated cohort (in multivariable models, HR for PFS: 1.79, 95% CI: 1.13 to 2.83, p=0.014, and for OS: 2.33, 95% CI: 1.36 to 3.98, p=0.002). …”
Get full text

Presenting the model of portfolio management in investment funds based on behavioral financial variables by Seyed Mohammad Hadi Shahamat, Mahdi Mohammad Bagheri, Ali Raispour Rajabali, Mohsen Zayandeh Roudi

“…Asset allocation is the division of assets in the portfolio between risky and risk-free asset classes. Typically, investing requires the careful design of an investment policy statement that appeals to the unique needs of investors. …”
Get full text

Construction and efficacy of recombinant Newcastle disease virus co-expressing VP2 and VP3 proteins of very virulent infectious bursal disease virus by Tongfei Liu, Lin Lin, Yun Pan, Xiaoling Lin, Ming Liang, Guanming Shao, Keyu Feng, Yaxin Liu, Xinheng Zhang, Qingmei Xie

“…The genetic stability and growth pattern of rNDV were evaluated and its immunogenicity was assessed in specific pathogen free (SPF) chickens. rNDV-VP2-VP3 vaccines induced higher levels of neutralising antibodies, no damage to immune organs, and significantly lower viral loads in the bursa of the falciparum. rNDV-VP2 group showed partial protection, while the placebo group exhibited severe lesions and higher mortality, suggesting that the vaccine was effective in preventing IBDV-induced damage. …”
Get full text

True Mass and Atmospheric Composition of the Nontransiting Hot Jupiter HD 143105 b by Luke Finnerty, Yinzi Xin, Jerry W. Xuan, Julie Inglis, Michael P. Fitzgerald, Shubh Agrawal, Ashley Baker, Randall Bartos, Geoffrey A. Blake, Benjamin Calvin, Sylvain Cetre, Jacques-Robert Delorme, Greg Doppmann, Daniel Echeverri, Katelyn Horstman, Chih-Chun Hsu, Nemanja Jovanovic, Joshua Liberman, Ronald A. López, Emily C. Martin, Dimitri Mawet, Evan Morris, Jacklyn Pezzato-Rovner, Jean-Baptiste Ruffio, Ben Sappey, Tobias Schofield, Andrew Skemer, Taylor Venenciano, J. Kent Wallace, Nicole L. Wallack, Jason J. Wang, Ji Wang

“…Retrieval analysis indicates the atmosphere of HD 143105 b is cloud free to approximately 1 bar and dominated by H _2 O absorption ( ${\mathrm{logH}}_{2}{{\rm{O}}}_{\mathrm{MMR}}=-3.{9}_{-0.5}^{+0.8}$ ), placing only an upper limit on the CO abundance ( ${\mathrm{logCO}}_{\mathrm{MMR}}\lt -3.7$ at 95% confidence). …”
Get full text